Shiyao Group: The first dual-target CAR-T cell injection based on mRNA-LNP has obtained clinical trial approval in China.

Shiyao Group announced that the first dual-target chimeric antigen receptor-T cell injection based on mRNA-LNP developed by the group has been approved by the National Medical Products Administration of the People's Republic of China and can conduct clinical trials in China.